Form 4: Tourmaline Bio Director Sells Shares in Novartis Merger

Mark McDade, a director of Tourmaline Bio, Inc., disposed of all his direct and indirect holdings and stock options following the company's acquisition by Novartis AG for $48.00 per share.

Summary

• Mark McDade, a Director of Tourmaline Bio, Inc. (TRML), reported the disposal of all his beneficial ownership in the company.
• The transactions occurred on October 28, 2025, pursuant to the Agreement and Plan of Merger dated September 8, 2025.
• Novartis AG, through its subsidiary Torino Merger Sub Inc., completed a cash tender offer to acquire all outstanding common stock of Tourmaline Bio, Inc.
• Each common share was acquired for $48.00 in cash.
• McDade directly disposed of 518 shares of common stock.
• He indirectly disposed of 183,177 shares held by Qiming U.S. Healthcare Fund I, L.P., 110,083 shares held by Qiming U.S. Healthcare Fund II, L.P., and 448,431 shares held by Qiming U.S. Healthcare Fund III, L.P.
• All outstanding and unexercised employee stock options were canceled and converted into a cash payment.
• Options with exercise prices of $9.46 (20,000 shares), $13.91 (10,000 shares), and $18.73 (16,800 shares) were disposed of.
• The cash payment for options was calculated as the product of (Merger Consideration Exercise Price) and the number of shares issuable upon exercise.

Sentiment

Score: 8

Explanation: The successful completion of the merger at a fixed cash price of $48.00 per share, significantly above the exercise prices of the disposed options, represents a favorable outcome for the reporting person and other shareholders.

Positives

• Successful completion of the merger provides liquidity to Tourmaline Bio shareholders at a fixed cash price.
• Option holders received cash for their in-the-money options, reflecting a significant gain over their exercise prices.
• The merger consideration of $48.00 per share represents a favorable outcome for shareholders and option holders.

Negatives

• Tourmaline Bio, Inc. ceases to be an independent publicly traded company.
• Shareholders no longer have equity participation in the future growth or potential upside of Tourmaline Bio as a standalone entity.

Future Outlook

NA

Industry Context

The acquisition of Tourmaline Bio by Novartis AG reflects a continuing trend of consolidation within the biotechnology and pharmaceutical sectors, where larger companies seek to expand their pipelines and capabilities through strategic acquisitions of smaller, innovative firms.

Related Party Transactions

• Mark McDade, as a managing member of the general partners for Qiming U.S. Healthcare Fund I, L.P., Qiming U.S. Healthcare Fund II, L.P., and Qiming U.S. Healthcare Fund III, L.P., may be deemed to share voting and dispositive power over the securities held by these funds. He disclaims beneficial ownership except to the extent of his pecuniary interest.

Stakeholder Impact

• Shareholders: Received $48.00 cash per share, concluding their equity investment in Tourmaline Bio.
• Employees (option holders): Received cash for their vested stock options, realizing value from their equity compensation.
• Tourmaline Bio: Ceased to exist as an independent public entity, becoming an indirect wholly owned subsidiary of Novartis AG.

Key Dates

Keywords

Tourmaline Bio, TRML, Novartis, Merger, Acquisition, Form 4, Insider Transaction, Stock Options, Qiming, Healthcare